CL2007002567A1 - Proteinas aisladas de enlace a activina a humana. - Google Patents

Proteinas aisladas de enlace a activina a humana.

Info

Publication number: CL2007002567A1
Authority: CL; Chile
Prior art keywords: activine; link; human; isolated proteins; proteins
Prior art date: 2006-09-08

Application number

CL200702567A

Other languages

English (en)

Inventor

Qing Han Hq Kwak Keith So Chen

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-08

Filing date

2007-09-04

Publication date

2008-02-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39103486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002567(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-04 Application filed by Amgen Inc filed Critical Amgen Inc

2008-02-01 Publication of CL2007002567A1 publication Critical patent/CL2007002567A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL200702567A 2006-09-08 2007-09-04 Proteinas aisladas de enlace a activina a humana. CL2007002567A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84343006P	2006-09-08	2006-09-08
US95665307P	2007-08-17	2007-08-17

Publications (1)

Publication Number	Publication Date
CL2007002567A1 true CL2007002567A1 (es)	2008-02-01

Family

ID=39103486

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702567A CL2007002567A1 (es)	2006-09-08	2007-09-04	Proteinas aisladas de enlace a activina a humana.

Country Status (22)

Country	Link
US (5)	US8309082B2 (es)
EP (5)	EP3495388A1 (es)
JP (3)	JP5497438B2 (es)
AR (1)	AR062703A1 (es)
AU (1)	AU2007294580C1 (es)
CA (1)	CA2661878C (es)
CL (1)	CL2007002567A1 (es)
CY (2)	CY1116037T1 (es)
DK (2)	DK2559705T3 (es)
ES (2)	ES2596184T3 (es)
HR (2)	HRP20150171T1 (es)
HU (1)	HUE030463T2 (es)
LT (1)	LT2559705T (es)
ME (1)	ME02539B (es)
MX (1)	MX2009002571A (es)
PE (1)	PE20080914A1 (es)
PL (2)	PL2559705T3 (es)
PT (2)	PT2064239E (es)
RS (2)	RS53819B1 (es)
SI (2)	SI2064239T1 (es)
TW (1)	TW200819466A (es)
WO (1)	WO2008031061A2 (es)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3489257A1 (en)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
US8067562B2 (en)	2005-11-01	2011-11-29	Amgen Inc.	Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
ES2839549T3 (es)	2005-11-23	2021-07-05	Acceleron Pharma Inc	Antagonistas de activina-ActRIIa de utilización en la estimulación del crecimiento óseo
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (es) *	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
ME02335B (me)	2006-12-18	2013-04-30	Acceleron Pharma Inc	Activin-actrii antagonisti i upotreba za liječenje anemije
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es)	2007-02-01	2009-10-12	Acceleron Pharma Inc	Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
BRPI0807506B1 (pt)	2007-02-09	2022-02-15	Acceleron Pharma, Inc	Uso de uma proteína de fusão actriia-fc para a fabricação de um medicamento para tratar ou previnir mieloma múltiplo
US8501678B2 (en)	2007-03-06	2013-08-06	Atara Biotherapeutics, Inc.	Variant activin receptor polypeptides and uses thereof
TW201718635A (zh)	2007-03-06	2017-06-01	安美基公司	變異之活動素受體多肽及其用途
US20110097318A1 (en) *	2007-08-31	2011-04-28	Amgen Inc.	Solid-State Protein Formulation
EP2207562B1 (en)	2007-09-18	2017-05-31	Acceleron Pharma, Inc.	Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PL3494986T3 (pl)	2008-08-14	2020-11-16	Acceleron Pharma Inc.	Pułapki GDF
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN102245634B (zh)	2008-11-26	2014-10-08	安姆根有限公司	激活素iib受体多肽的变异体及其用途
CA2749544A1 (en)	2009-01-13	2010-07-22	Acceleron Pharma Inc.	Methods for increasing adiponectin
JP5912078B2 (ja)	2009-06-08	2016-04-27	アクセルロンファーマ，インコーポレイテッド	熱発生性脂肪細胞を増加させるための方法
JP2012529294A (ja)	2009-06-12	2012-11-22	アクセルロンファーマ，インコーポレイテッド	切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
AU2010310457B2 (en)	2009-10-23	2015-07-02	Amgen Inc.	Vial adapter and system
CA2781152A1 (en)	2009-11-17	2011-05-26	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar)	2010-05-26	2019-03-13	Regeneron Pharma	مضادات حيوية لـعامل تمايز النمو 8 البشري
PT2575935E (pt)	2010-06-07	2015-10-20	Amgen Inc	Dispositivo de administração de medicamento
CN105440134A (zh)	2010-08-16	2016-03-30	安姆根公司	结合肌肉生长抑制素的抗体、组合物和方法
EP2638065A4 (en) *	2010-11-08	2014-04-09	Acceleron Pharma Inc	ACTRIIA-BINDING SUBSTANCES AND ITS USES
MX341790B (es)	2011-03-31	2016-09-02	Amgen Inc	Adaptador de viales y sistema.
CA3021845C (en)	2011-04-20	2022-03-29	Amgen Inc.	Autoinjector apparatus
SMT201800287T1 (it)	2011-10-14	2018-07-17	Amgen Inc	Iniettore e metodo di assiemaggio
AU2012339722B2 (en)	2011-11-14	2017-09-14	Regeneron Pharmaceuticals, Inc.	Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
KR20140108562A (ko)	2011-12-19	2014-09-11	암젠 인코퍼레이티드	변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도
NZ707477A (en)	2012-11-02	2019-09-27	Celgene Corp	Activin-actrii antagonists and uses for treating bone and other disorders
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
AU2013348071B2 (en)	2012-11-21	2018-05-24	Amgen Inc.	Drug delivery device
KR20150136061A (ko) *	2013-02-01	2015-12-04	산타 마리아 바이오테라퓨틱스, 인코포레이티드	대상에 항-액티빈-a 화합물의 투여
JP6336564B2 (ja)	2013-03-15	2018-06-06	アムゲン・インコーポレーテッド	薬物カセット、自動注入器、および自動注入器システム
TWI639453B (zh)	2013-03-15	2018-11-01	美商安美基公司	用於注射器之匣盒
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
CN113559363B (zh)	2013-03-22	2023-10-31	美国安进公司	注射器及装配方法
TWI655207B (zh) *	2013-07-30	2019-04-01	再生元醫藥公司	抗活化素ａ之抗體及其用途
EP3041863A4 (en)	2013-09-05	2017-08-16	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6546178B2 (ja)	2013-09-13	2019-07-17	ジェネンテック，インコーポレイテッド	細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
EP4331605A3 (en)	2013-09-13	2024-05-22	F. Hoffmann-La Roche AG	Methods and compositions comprising purified recombinant polypeptides
EP3789064B1 (en)	2013-10-24	2024-11-27	Amgen Inc.	Injector and method of assembly
WO2015061389A1 (en)	2013-10-24	2015-04-30	Amgen Inc.	Drug delivery system with temperature-sensitive control
WO2015119906A1 (en)	2014-02-05	2015-08-13	Amgen Inc.	Drug delivery system with electromagnetic field generator
SG11201609219QA (en)	2014-05-07	2016-12-29	Amgen Inc	Autoinjector with shock reducing elements
EP3143404B1 (en)	2014-05-16	2018-08-29	Amgen Inc.	Assay for detecting th1 and th2 cell populations
US20170124285A1 (en)	2014-06-03	2017-05-04	Amgen Inc.	Devices and methods for assisting a user of a drug delivery device
TN2016000553A1 (en)	2014-06-13	2018-04-04	Acceleron Pharma Inc	Methods and compositions for treating ulcers
US20160075772A1 (en)	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MX392725B (es)	2014-10-14	2025-03-24	Amgen Inc	Dispositivo de inyeccion de farmaco con indicadores visuales y audibles.
EP4233889A3 (en)	2014-12-03	2023-10-11	Celgene Corporation	Activin-actrii antagonists and uses for treating myelodysplastic syndrome
JP6716566B2 (ja)	2014-12-19	2020-07-01	アムジエン・インコーポレーテツド	近接センサ付き薬物送達装置
WO2016100055A1 (en)	2014-12-19	2016-06-23	Amgen Inc.	Drug delivery device with live button or user interface field
US10583245B2 (en)	2015-02-17	2020-03-10	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es)	2015-02-27	2022-04-12	Amgen Inc	Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
EA039118B1 (ru) *	2015-04-01	2021-12-07	Ридженерон Фармасьютикалз, Инк.	Способ лечения прогрессирующей оссифицирующей фибродисплазии
KR20170135967A (ko)	2015-04-15	2017-12-08	리제너론 파마슈티칼스 인코포레이티드	Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
AU2016255768B2 (en)	2015-04-29	2022-03-10	Regeneron Pharmaceuticals, Inc.	Treatment of fibrodysplasia ossificans progressiva
WO2016205042A1 (en) *	2015-06-16	2016-12-22	The Board Of Trustees Of The Leland Stanford Junior University	SIRPα AGONIST ANTIBODY
MX2018001522A (es)	2015-08-05	2018-03-15	Janssen Biotech Inc	Anticuerpos anti-cd154 y metodos de uso de estos.
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
WO2017100501A1 (en)	2015-12-09	2017-06-15	Amgen Inc.	Auto-injector with signaling cap
WO2017120178A1 (en)	2016-01-06	2017-07-13	Amgen Inc.	Auto-injector with signaling electronics
BR112018014810A2 (pt)	2016-01-22	2018-12-11	Merck Sharp & Dohme Corp.	anticorpos anti-fator xi de coagulação
EP3413912A4 (en)	2016-02-11	2019-09-25	The Johns Hopkins University	COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING FOR THE TREATMENT OF CANCER
ES2814287T3 (es)	2016-03-15	2021-03-26	Amgen Inc	Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en)	2016-05-13	2022-12-22	Amgen Inc.	Vial sleeve assembly
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
EP3465124B1 (en)	2016-06-03	2026-02-11	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
IL315266A (en)	2016-06-14	2024-10-01	Merck Sharp ַ& Dohme Llc	Anti-coagulation factor xi antibodies
WO2018004842A1 (en)	2016-07-01	2018-01-04	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
EP3532127A1 (en)	2016-10-25	2019-09-04	Amgen Inc.	On-body injector
EP3570917A1 (en)	2017-01-17	2019-11-27	Amgen Inc.	Injection devices and related methods of use and assembly
AU2018220538B2 (en)	2017-02-17	2023-12-14	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Insertion mechanism for drug delivery device
WO2018165143A1 (en)	2017-03-06	2018-09-13	Amgen Inc.	Drug delivery device with activation prevention feature
IL268478B2 (en)	2017-03-07	2023-10-01	Amgen Inc	Inserting a needle using super pressure
MX2019010671A (es)	2017-03-09	2019-10-21	Amgen Inc	Mecanismo de insercion para dispositivo de administracion de farmacos.
US12503700B2 (en)	2017-03-14	2025-12-23	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
KR102651078B1 (ko)	2017-03-28	2024-03-22	암겐 인코포레이티드	플런저 로드 및 주사기 조립 시스템 및 방법
CA3061982A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
EP3634546A1 (en)	2017-06-08	2020-04-15	Amgen Inc.	Torque driven drug delivery device
CN110997725B (zh) *	2017-06-12	2024-08-09	蓝鳍生物医药公司	抗-il1rap抗体和抗体药物缀合物
AU2018288604B2 (en)	2017-06-22	2023-12-21	Amgen Inc.	Device activation impact/shock reduction
MA49461A (fr)	2017-06-23	2020-04-29	Amgen Inc	Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
JP7408398B2 (ja)	2017-07-14	2024-01-05	アムジエン・インコーポレーテツド	二重ねじりばねシステムを有する針挿入後退システム
WO2019018169A1 (en)	2017-07-21	2019-01-24	Amgen Inc.	PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
MA49677A (fr)	2017-07-25	2021-04-21	Amgen Inc	Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
JP7242562B2 (ja)	2017-07-25	2023-03-20	アムジエン・インコーポレーテツド	容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
US12318593B2 (en)	2017-08-09	2025-06-03	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en)	2017-08-18	2019-02-21	Amgen Inc.	BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
MA50611A (fr)	2017-10-04	2020-08-12	Amgen Inc	Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
CN111132711B (zh)	2017-10-06	2022-07-01	安进公司	带有联锁组件的药物递送装置及相关组装方法
EP3694578B1 (en)	2017-10-09	2025-09-24	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
IL273663B2 (en)	2017-11-03	2025-05-01	Amgen Inc	System and methods for disinfecting a drug delivery device
WO2019090303A1 (en)	2017-11-06	2019-05-09	Amgen Inc.	Fill-finish assemblies and related methods
ES2994389T3 (en)	2017-11-06	2025-01-23	Amgen Inc	Drug delivery device with placement and flow sensing
MA50557A (fr)	2017-11-10	2020-09-16	Amgen Inc	Pistons pour dispositifs d'administration de médicament
JP7370969B2 (ja)	2017-11-16	2023-10-30	アムジエン・インコーポレーテツド	薬物送達デバイスの扉ラッチ機構
JP7747438B2 (ja)	2017-11-16	2025-10-01	アムジエン・インコーポレーテツド	失速及び終点検出を有するオートインジェクタ
IL321873A (en)	2018-03-01	2025-08-01	Regeneron Pharma	Methods for altering body composition
US12325737B2 (en)	2018-03-26	2025-06-10	Amgen Inc.	Total afucosylated glycoforms of antibodies produced in cell culture
DK3773713T3 (da)	2018-04-06	2025-08-18	Regeneron Pharma	Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
MA53379A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
WO2020023451A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
US12303677B2 (en)	2018-07-24	2025-05-20	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
MA53320A (fr)	2018-07-31	2021-11-03	Amgen Inc	Ensemble de trajet de fluide pour dispositif d'administration de médicament
MA53724A (fr)	2018-09-24	2021-12-29	Amgen Inc	Systèmes et procédés de dosage interventionnel
CA3110371A1 (en)	2018-09-28	2020-04-02	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
CN117159846A (zh)	2018-10-02	2023-12-05	安进公司	具有内部力传递的用于药物递送的注射系统
WO2020072846A1 (en)	2018-10-05	2020-04-09	Amgen Inc.	Drug delivery device having dose indicator
AR116704A1 (es)	2018-10-15	2021-06-02	Amgen Inc	Dispositivo de administración de fármacos con mecanismo de amortiguación
SG11202101824VA (en)	2018-10-15	2021-03-30	Amgen Inc	Platform assembly process for drug delivery device
IL281908B2 (en)	2018-11-01	2025-06-01	Amgen Inc	Drug delivery devices with partial drug delivery member retraction
ES3010833T3 (en)	2018-11-01	2025-04-04	Amgen Inc	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
CN113195532B (zh)	2018-12-18	2025-04-11	瑞泽恩制药公司	使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
US20220160972A1 (en)	2019-04-24	2022-05-26	Amgen Inc.	Syringe sterilization verification assemblies and methods
AU2020284038A1 (en) *	2019-05-30	2021-12-02	Acceleron Pharma Inc.	ActRII-binding proteins and uses thereof
EP4017560A2 (en)	2019-08-23	2022-06-29	Amgen, Inc	Drug delivery device with configurable needle shield engagement components and related methods
CN114450593A (zh)	2019-09-26	2022-05-06	美国安进公司	产生抗体组合物的方法
CA3164168A1 (en)	2020-01-08	2021-07-15	Regeneron Pharmaceuticals, Inc.	Treatment of fibrodysplasia ossificans progressiva
US20230273126A1 (en)	2020-06-04	2023-08-31	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4200017A1 (en)	2020-08-20	2023-06-28	Regeneron Pharmaceuticals, Inc.	Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
JP2023548767A (ja)	2020-10-15	2023-11-21	アムジエン・インコーポレーテツド	抗体製造方法における相対不対グリカン
EP4243931A4 (en) *	2020-11-11	2025-01-01	HAN, Hq	BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF
WO2022140670A2 (en) *	2020-12-23	2022-06-30	Phenomic Ai	Anti-activin antibodies and methods of using the same
MX2023013640A (es)	2021-05-21	2023-11-30	Amgen Inc	Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
EP4352094A1 (en)	2021-06-07	2024-04-17	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
US20250076309A1 (en)	2021-10-05	2025-03-06	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
CA3235627A1 (en) *	2021-10-18	2023-04-27	Byomass Inc.	Anti-activin a antibodies, compositions and uses thereof
WO2023147107A1 (en) *	2022-01-31	2023-08-03	Byomass Inc.	Myeloproliferative conditions
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
EP4590698A1 (en)	2022-09-21	2025-07-30	Regeneron Pharmaceuticals, Inc.	Methods of treating obesity, diabetes, and liver dysfunction
AU2024256160A1 (en)	2023-04-20	2025-10-02	Amgen Inc.	Methods of determining relative unpaired glycan content
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US32011A (en)		1861-04-09		Coffee-pot
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4411993A (en)	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
USRE32011E (en)	1981-12-14	1985-10-22	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja)	1982-01-06	1983-07-13	Toray Ind Inc	感光性樹脂組成物
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en)	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en)	1984-12-03	1990-02-20	Teijin Limited	Monoclonal antibody to human protein C
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4973577A (en)	1986-04-04	1990-11-27	The Salk Institute For Biological Studies	FSH-releasing peptides
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
JPH01171495A (ja) *	1987-12-25	1989-07-06	Ajinomoto Co Inc	モノクローナル抗体及びそれを用いる定量法
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
NZ257942A (en)	1992-10-23	1996-04-26	Immunex Corp	Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
US5545616A (en) *	1994-09-22	1996-08-13	Genentech, Inc.	Method for predicting and/or preventing preterm labor
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US6133426A (en)	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
DE69839147T2 (de)	1997-06-12	2009-02-19	Novartis International Pharmaceutical Ltd.	Künstliche antikörperpolypeptide
JP3897068B2 (ja) *	1997-08-28	2007-03-22	日本ゼオン株式会社	アクリルゴム組成物
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
GB9928787D0 (en)	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
JP4487376B2 (ja)	2000-03-31	2010-06-23	味の素株式会社	腎疾患治療剤
AU2001265198A1 (en)	2000-06-01	2001-12-11	Amgen Inc.	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
GB0025144D0 (en)	2000-10-13	2000-11-29	Medical Res Council	Concatenated nucleic acid sequences
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
EP1539233B1 (en)	2001-07-12	2011-04-27	FOOTE, Jefferson	Super humanized antibodies
AUPR638101A0 (en)	2001-07-13	2001-08-09	Bioa Pty Limited	Composition and method for treatment of disease
EP1406929A2 (en)	2001-07-18	2004-04-14	MERCK PATENT GmbH	Glycoprotein vi fusion proteins
US20040202995A1 (en)	2003-04-09	2004-10-14	Domantis	Nucleic acids, proteins, and screening methods
DK1648998T3 (en)	2003-07-18	2015-01-05	Amgen Inc	Specific binding agents for hepatocyte growth factor
US7514534B2 (en)	2003-11-19	2009-04-07	Dyax Corp.	Metalloproteinase-binding proteins
EP1740208A2 (en)	2004-03-23	2007-01-10	Amgen, Inc	Monoclonal antibodies specific for human ox40l (cd134l)
EP1796711A2 (en)	2004-04-22	2007-06-20	Oregon Health and Science University	Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
CA2563374A1 (en) *	2004-04-27	2005-12-08	Research Development Foundation	Antagonism of tgf-.beta.superfamily receptor signaling
EP1824886B1 (en)	2004-11-17	2010-12-22	Amgen Inc.	Fully human monoclonal antibodies to il-13
EP2361933A3 (en)	2005-01-26	2012-05-02	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
JP2006249083A (ja) *	2005-03-08	2006-09-21	Pharmacia & Upjohn Co Llc	抗ｍ−ｃｓｆ抗体組成物
ZA200709291B (en)	2005-04-25	2009-01-28	Pfizer	Antibodies to myostatin
CN101517068B (zh)	2005-09-07	2017-02-08	安进弗里蒙特公司	活化素受体样激酶‑1的人单克隆抗体
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
EP2207562B1 (en)	2007-09-18	2017-05-31	Acceleron Pharma, Inc.	Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
CN102245634B (zh)	2008-11-26	2014-10-08	安姆根有限公司	激活素iib受体多肽的变异体及其用途
ES2613523T3 (es)	2009-09-09	2017-05-24	Acceleron Pharma, Inc.	Antagonistas de ActRIIb y dosificación y usos de los mismos
US20120295814A1 (en)	2010-01-08	2012-11-22	The Brigham And Women's Hospital, Inc.	CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
CA2794513A1 (en)	2010-03-31	2011-10-06	Aeterna Zentaris Gmbh	Perifosine and capecitabine as a combined treatment for cancer
EP2638065A4 (en)	2010-11-08	2014-04-09	Acceleron Pharma Inc	ACTRIIA-BINDING SUBSTANCES AND ITS USES
EP2802308A1 (en)	2012-01-13	2014-11-19	Allergan, Inc.	Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
TWI655207B (zh) *	2013-07-30	2019-04-01	再生元醫藥公司	抗活化素ａ之抗體及其用途

2007
- 2007-09-04 CL CL200702567A patent/CL2007002567A1/es unknown
- 2007-09-06 TW TW096133216A patent/TW200819466A/zh unknown
- 2007-09-07 SI SI200731605T patent/SI2064239T1/sl unknown
- 2007-09-07 EP EP18203136.9A patent/EP3495388A1/en active Pending
- 2007-09-07 RS RS20150075A patent/RS53819B1/sr unknown
- 2007-09-07 HR HRP20150171TT patent/HRP20150171T1/hr unknown
- 2007-09-07 ES ES12154124.7T patent/ES2596184T3/es active Active
- 2007-09-07 HU HUE12154124A patent/HUE030463T2/en unknown
- 2007-09-07 DK DK12154124.7T patent/DK2559705T3/en active
- 2007-09-07 PL PL12154124T patent/PL2559705T3/pl unknown
- 2007-09-07 EP EP12154124.7A patent/EP2559705B1/en not_active Revoked
- 2007-09-07 LT LTEP12154124.7T patent/LT2559705T/lt unknown
- 2007-09-07 JP JP2009527594A patent/JP5497438B2/ja active Active
- 2007-09-07 EP EP07842088.2A patent/EP2064239B1/en active Active
- 2007-09-07 AU AU2007294580A patent/AU2007294580C1/en active Active
- 2007-09-07 PT PT78420882T patent/PT2064239E/pt unknown
- 2007-09-07 CA CA2661878A patent/CA2661878C/en active Active
- 2007-09-07 AR ARP070103960A patent/AR062703A1/es unknown
- 2007-09-07 PT PT121541247T patent/PT2559705T/pt unknown
- 2007-09-07 MX MX2009002571A patent/MX2009002571A/es active IP Right Grant
- 2007-09-07 WO PCT/US2007/077923 patent/WO2008031061A2/en not_active Ceased
- 2007-09-07 EP EP16178026.7A patent/EP3133084B1/en active Active
- 2007-09-07 SI SI200731843A patent/SI2559705T1/sl unknown
- 2007-09-07 ES ES07842088.2T patent/ES2528798T3/es active Active
- 2007-09-07 PL PL07842088T patent/PL2064239T3/pl unknown
- 2007-09-07 US US11/851,884 patent/US8309082B2/en active Active
- 2007-09-07 DK DK07842088.2T patent/DK2064239T3/da active
- 2007-09-07 EP EP20175809.1A patent/EP3730517A1/en active Pending
- 2007-09-07 RS RS20160851A patent/RS55100B1/sr unknown
- 2007-09-07 ME MEP-2016-224A patent/ME02539B/me unknown
- 2007-09-07 PE PE2007001204A patent/PE20080914A1/es not_active Application Discontinuation
2012
- 2012-07-16 US US13/550,447 patent/US8753627B2/en active Active
2013
- 2013-02-20 JP JP2013030740A patent/JP5986518B2/ja active Active
2014
- 2014-04-24 US US14/260,856 patent/US20150086556A1/en not_active Abandoned
2015
- 2015-01-29 CY CY20151100092T patent/CY1116037T1/el unknown
2016
- 2016-05-06 JP JP2016092915A patent/JP6457431B2/ja active Active
- 2016-10-10 HR HRP20161300TT patent/HRP20161300T1/hr unknown
- 2016-10-13 CY CY20161101023T patent/CY1118693T1/el unknown
- 2016-11-08 US US15/346,617 patent/US10100109B2/en active Active
2018
- 2018-09-12 US US16/128,831 patent/US11542325B2/en active Active

Also Published As

Publication number	Publication date
WO2008031061A3 (en)	2008-07-31
TW200819466A (en)	2008-05-01
US8309082B2 (en)	2012-11-13
PT2559705T (pt)	2016-10-17
PT2064239E (pt)	2015-02-09
JP2013107899A (ja)	2013-06-06
EP2559705A3 (en)	2013-06-05
LT2559705T (lt)	2016-10-25
RS53819B1 (sr)	2015-06-30
HRP20161300T1 (hr)	2016-11-18
PL2559705T3 (pl)	2017-01-31
EP2064239A2 (en)	2009-06-03
EP3133084B1 (en)	2020-06-24
WO2008031061A2 (en)	2008-03-13
EP2559705A2 (en)	2013-02-20
EP3495388A1 (en)	2019-06-12
MX2009002571A (es)	2009-06-19
SI2064239T1 (sl)	2015-03-31
PL2064239T3 (pl)	2015-05-29
SI2559705T1 (sl)	2016-12-30
JP6457431B2 (ja)	2019-01-23
US20130030159A1 (en)	2013-01-31
DK2064239T3 (en)	2015-02-16
US20180371073A1 (en)	2018-12-27
EP2559705B1 (en)	2016-07-13
US20090234106A1 (en)	2009-09-17
CY1116037T1 (el)	2017-01-25
EP3730517A1 (en)	2020-10-28
JP5986518B2 (ja)	2016-09-06
DK2559705T3 (en)	2016-10-31
CA2661878C (en)	2018-08-28
RS55100B1 (sr)	2016-12-30
EP2064239B1 (en)	2014-11-26
US11542325B2 (en)	2023-01-03
US20150086556A1 (en)	2015-03-26
EP3133084A1 (en)	2017-02-22
JP5497438B2 (ja)	2014-05-21
ES2596184T3 (es)	2017-01-05
JP2010502740A (ja)	2010-01-28
CA2661878A1 (en)	2008-03-13
AR062703A1 (es)	2008-11-26
AU2007294580B2 (en)	2012-09-20
HUE030463T2 (en)	2017-05-29
US10100109B2 (en)	2018-10-16
AU2007294580C1 (en)	2013-08-22
JP2016146844A (ja)	2016-08-18
HRP20150171T1 (hr)	2015-05-22
ME02539B (me)	2017-02-20
PE20080914A1 (es)	2008-09-17
US8753627B2 (en)	2014-06-17
US20170073408A1 (en)	2017-03-16
CY1118693T1 (el)	2017-07-12
AU2007294580A1 (en)	2008-03-13
ES2528798T3 (es)	2015-02-12

Publication	Publication Date	Title
CL2007002567A1 (es)	2008-02-01	Proteinas aisladas de enlace a activina a humana.
EP1954596A4 (en)	2009-12-23	DISTRIBUTOR
DE602007014221D1 (de)	2011-06-09	Chromenverbindung
DK2046826T3 (da)	2011-10-24	Exendin-fusionsproteiner
ATE513831T1 (de)	2011-07-15	Pyridinä3,4-büpyrazinone
ATE499453T1 (de)	2011-03-15	Zugerichtetes leder
DE602007000274D1 (de)	2009-01-08	Mähdrescher
DE502007004163D1 (de)	2010-08-05	Ketten-Verschlussglied
EP2072519A4 (en)	2009-10-21	DIARYLKETIMINDERIVAT
EP2103607A4 (en)	2011-01-05	1-phenyl-1-thio-D-GLUCITOLDERIVAT
EP2006577A4 (en)	2011-01-19	CONNECTION MECHANISM
ATE531279T1 (de)	2011-11-15	Teilweise hydrolysiertes getreideprotein
ES2896053T8 (es)	2022-03-03	Biogel
DE602007001499D1 (de)	2009-08-20	Hebelverbinder
DE502007001364D1 (de)	2009-10-01	Tevorrichtung
FR2937670B1 (fr)	2013-01-18	Systeme de trappe.
FI20070846L (fi)	2008-05-11	Releliitin
FI20070847L (fi)	2008-05-11	Releliitin
DK2013136T3 (da)	2013-09-30	Sadeltræ
DE502007000809D1 (de)	2009-07-16	Gutaufnehmer
DE502007001097D1 (de)	2009-09-03	Lenkeranordnung
FI20060972A0 (fi)	2006-11-03	Instuntopohjainen viestintä
ES1066333Y (es)	2008-04-01	Reloj de pulsera.
EP1877948A4 (en)	2010-07-14	NATIVE DICTATION SYSTEM
ES1062228Y (es)	2006-08-16	Cosechadora de aceitunas